AbbVie (NYSE:ABBV) Trading Up 1.3% – Should You Buy?

AbbVie Inc. (NYSE:ABBV)’s stock price traded up 1.3% on Tuesday . The company traded as high as $262.27 and last traded at $259.87. 3,804,536 shares were traded during trading, a decline of 44% from the average session volume of 6,734,232 shares. The stock had previously closed at $256.42.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie reported that its investigational multiple myeloma therapy, etentamig, met both primary endpoints in the Phase 3 CERVINO trial. The drug produced a 74% objective response rate and reduced the risk of disease progression or death by 60% versus standard therapies. Its monthly dosing schedule, low rate of cytokine release syndrome and potential for outpatient use could help it compete in the growing multiple myeloma market. AbbVie CERVINO trial results
• Positive Sentiment: The strong late-stage results improve AbbVie’s oncology pipeline and could eventually provide a new growth driver as the company manages the loss of Humira exclusivity. If approved, etentamig could take market share from existing BCMA-directed treatments, including Johnson & Johnson’s Tecvayli. Etentamig multiple myeloma market outlook
• Positive Sentiment: AbbVie completed its approximately $10.9 billion cash acquisition of Apogee Therapeutics, adding late-stage and early-stage immunology assets. Lead drug candidate zumilokibart targets IL-13 for atopic dermatitis, while APG273 targets IL-13 and TSLP for asthma, broadening AbbVie’s dermatology and respiratory pipeline. AbbVie completes Apogee acquisition
• Neutral Sentiment: AbbVie reaffirmed its 2026 adjusted EPS guidance of $13.87 to $14.07 and third-quarter guidance of $3.84 to $3.88, indicating that the Apogee transaction has not changed near-term expectations. Management is scheduled to speak at the Morgan Stanley Global Healthcare Conference on September 15.
• Negative Sentiment: The Apogee purchase is expected to dilute earnings in the near term before becoming accretive around 2032, creating execution and valuation risk. Investors also continue to monitor Humira revenue erosion, as well as challenges in AbbVie’s oncology and aesthetics businesses, despite growth from Skyrizi, Rinvoq and neuroscience products. ABBV stock growth drivers and headwinds

Wall Street Analyst Weigh In

A number of analysts have issued reports on the stock. Wolfe Research upgraded shares of AbbVie from a “peer perform” rating to an “outperform” rating and set a $300.00 price target on the stock in a report on Thursday, August 13th. Weiss Ratings raised AbbVie from a “hold (c)” rating to a “buy (b-)” rating in a report on Tuesday, August 4th. BNP Paribas Exane boosted their price target on shares of AbbVie from $218.00 to $247.00 and gave the company a “neutral” rating in a report on Tuesday, August 11th. Bank of America upped their target price on AbbVie from $234.00 to $276.00 and gave the stock a “buy” rating in a report on Friday, July 10th. Finally, Morgan Stanley reaffirmed an “overweight” rating and set a $296.00 target price on shares of AbbVie in a research report on Monday, August 3rd. Two analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $275.95.

AbbVie Stock Down 0.2%

The stock has a fifty day moving average price of $254.23 and a two-hundred day moving average price of $229.67. The company has a market cap of $461.49 billion, a price-to-earnings ratio of 73.79, a P/E/G ratio of 1.18 and a beta of 0.29.

AbbVie (NYSE:ABBV) last posted its quarterly earnings results on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, topping the consensus estimate of $3.61 by $0.04. The business had revenue of $16.99 billion during the quarter, compared to the consensus estimate of $16.80 billion. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.The firm’s revenue for the quarter was up 10.2% compared to the same quarter last year. During the same period in the prior year, the company posted $2.97 EPS. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Analysts predict that AbbVie Inc. will post 14.05 earnings per share for the current fiscal year.

AbbVie Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, August 14th. Investors of record on Wednesday, July 15th were issued a $1.73 dividend. The ex-dividend date was Wednesday, July 15th. This represents a $6.92 dividend on an annualized basis and a yield of 2.6%. AbbVie’s dividend payout ratio is currently 195.48%.

Insider Buying and Selling

In other news, EVP Nicholas Donoghoe sold 32,710 shares of AbbVie stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the sale, the executive vice president directly owned 74,430 shares of the company’s stock, valued at approximately $18,607,500. This trade represents a 30.53% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 0.06% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the company. Brighton Jones LLC increased its stake in AbbVie by 17.4% during the fourth quarter. Brighton Jones LLC now owns 22,912 shares of the company’s stock worth $4,072,000 after acquiring an additional 3,401 shares during the last quarter. Revolve Wealth Partners LLC grew its holdings in AbbVie by 72.7% during the 4th quarter. Revolve Wealth Partners LLC now owns 7,279 shares of the company’s stock worth $1,294,000 after acquiring an additional 3,064 shares during the last quarter. Schnieders Capital Management LLC. grew its holdings in shares of AbbVie by 5.0% during the 2nd quarter. Schnieders Capital Management LLC. now owns 16,466 shares of the company’s stock worth $3,056,000 after purchasing an additional 789 shares in the last quarter. Ieq Capital LLC lifted its position in shares of AbbVie by 4.6% during the 2nd quarter. Ieq Capital LLC now owns 120,035 shares of the company’s stock worth $22,281,000 after buying an additional 5,274 shares in the last quarter. Finally, Worldquant Millennium Advisors LLC lifted its stake in shares of AbbVie by 117.3% in the 2nd quarter. Worldquant Millennium Advisors LLC now owns 1,135,034 shares of the company’s stock valued at $210,685,000 after purchasing an additional 612,702 shares during the period. 70.23% of the stock is currently owned by hedge funds and other institutional investors.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.